Shanghai Synergy Pharma Sciences EZH2 compound 28

Shanghai Synergy Pharma Sciences EZH2 compound 28: sourced facts only. name: "In vitro, 28 displayed potent EZH2 inhibition activity with an IC50 value of 0.95 nM, which is comparable to EPZ-6438 (1)." [PMID:37956762]; target: "In vitro, 28 displayed potent EZH2 inhibition activity with an IC50 value of 0.95 nM, which is comparable to EPZ-6438 (1)." [PMID:37956762]; developer: "Shanghai Synergy Pharmaceutical Sciences Co., Ltd., Shanghai, China." [PMID:37956762]; stage: "In vivo, 28 showed acceptable pharmacokinetic characteristics (oral bioavailability F = 36.9%) and better efficacy than 1 in both Pfeiffer and Karpas-422 xenograft mouse models, suggesting that it can be further developed as a potential therapeutic candidate for EZH2-associated cancers." [PMID:37956762]